Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2111268 | Cancer Genetics and Cytogenetics | 2008 | 5 Pages |
Abstract
The acute myeloid leukemia (AML) subtype M4Eo occurs in 5% of all AML cases and is usually associated with either an inv(16)(p13.1q22) or a t(16;16)(p13.1;q22) chromosomal abnormality. At the molecular level, these abnormalities generate a CBFB–MYH11 fusion gene. Patients with this genetic alteration are usually assigned to a low-risk group and thus receive standard chemotherapy. AML-M4Eo is rarely found in infants. We describe clinical, conventional banding, and molecular cytogenetic data for a 12-month-old baby with AML-M4Eo and a chimeric CBFB–MYH11 fusion gene masked by a novel rearrangement between chromosomes 1 and 16. This rearrangement characterizes a new type of inv(16)(p13.1q22) masked by a chromosome translocation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Maria Luiza Macedo Silva, Susana C. Raimondi, Eliana Abdelhay, Madeleine Gross, Hasmik Mkrtchyan, Amanda Faria de Figueiredo, Raul C. Ribeiro, Terezinha de Jesus Marques-Salles, Elaine S. Sobral, Marcelo Poirot Gerardin Land, Thomas Liehr,